| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.100.24.2449 |
| P698 | PubMed publication ID | 10595959 |
| P2093 | author name string | Nagai R | |
| Kudoh S | |||
| Oka T | |||
| Shimoyama M | |||
| Yazaki Y | |||
| Hayashi D | |||
| Zou Y | |||
| Komuro I | |||
| Takimoto E | |||
| Uozumi H | |||
| Shibasaki F | |||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2449-2454 | |
| P577 | publication date | 1999-12-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy | |
| P478 | volume | 100 |
| Q79304147 | Activation of calcineurin expression in ischemia‐reperfused rat heart and in human ischemic myocardium |
| Q35946043 | Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma |
| Q36430063 | Anchoring proteins as regulators of signaling pathways. |
| Q43840391 | Angiotensin II induced cardiac hypertrophy in vivo is inhibited by cyclosporin A in adult rats |
| Q35159705 | CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo |
| Q34641729 | Calcineurin and cardiac hypertrophy: where have we been? Where are we going? |
| Q34581528 | Calcineurin and hypertrophic heart disease: novel insights and remaining questions |
| Q54705010 | Calcineurin independent development of myocardial hypertrophy in transgenic rats overexpressing the mouse renin gene, TGR(mREN2)27. |
| Q34180391 | Calcineurin inhibition and cardiac hypertrophy: a matter of balance |
| Q37908184 | Calcineurin regulation of cytoskeleton organization: a new paradigm to analyse the effects of calcineurin inhibitors on the kidney |
| Q34243174 | Cardiac mechanotransduction: from sensing to disease and treatment |
| Q34076156 | Decoding calcium signals involved in cardiac growth and function |
| Q47448078 | Doppler evaluation of peripheral vascular adaptations to transverse aortic banding in mice |
| Q35876331 | Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk |
| Q45742115 | Effect of inhibition of glycogen synthase kinase-3 on cardiac hypertrophy during acute pressure overload |
| Q43255247 | Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca2+-ATPase activity in rat cardiac pressure-overload hypertrophy |
| Q34161036 | Effects of the calcineurin dependent signaling pathway inhibition by cyclosporin A on early and late cardiac remodeling following myocardial infarction |
| Q37430992 | Genetic inhibition of calcineurin induces diastolic dysfunction in mice with chronic pressure overload |
| Q39741034 | Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies |
| Q45903283 | Hypertrophy signaling pathways in experimental chronic aortic regurgitation. |
| Q34611013 | Increased expression of NF-AT3 and NF-AT4 in the atria correlates with procollagen I carboxyl terminal peptide and TGF-β1 levels in serum of patients with atrial fibrillation |
| Q44417798 | Inhibition of left ventricular remodelling preserves chamber systolic function in pressure-overloaded mice |
| Q34873552 | Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction |
| Q35128221 | Lactosylceramide promotes hypertrophy through ROS generation and activation of ERK1/2 in cardiomyocytes |
| Q33919182 | Meeting Koch's postulates for calcium signaling in cardiac hypertrophy |
| Q38265203 | MicroRNAs meet calcium: joint venture in ER proteostasis |
| Q34727513 | Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo |
| Q28216151 | NFAT signaling: choreographing the social lives of cells |
| Q24534634 | Novel human ZAKI-4 isoforms: hormonal and tissue-specific regulation and function as calcineurin inhibitors |
| Q44622908 | Pacing-induced calcineurin activation controls cardiac Ca2+ signalling and gene expression |
| Q28583542 | Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart |
| Q104070079 | Precision medicine for heart failure based on molecular mechanisms The Research Achievement Award Lecture |
| Q35818138 | Protective and Therapeutic Effects of Chinese Medicine Formula Jiajian Yunvjian on Experimental Cardiac Remodeling after Myocardial Infarction Induced by Coronary Artery Ligation |
| Q44112166 | Qindan capsule changes adventitial collagen synthesis in spontaneously hypertensive rats |
| Q35586569 | Role of calcineurin in striated muscle: development, adaptation, and disease |
| Q35121820 | Stretch-modulation of second messengers: effects on cardiomyocyte ion transport |
| Q85522346 | Syndecan-4 signaling via NFAT regulates extracellular matrix production and cardiac myofibroblast differentiation in response to mechanical stress |
| Q24309615 | Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth |
| Q28360110 | Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo |
| Q92624397 | The POU4F2/Brn-3b transcription factor is required for the hypertrophic response to angiotensin II in the heart |
| Q37793527 | What Causes a Broken Heart—Molecular Insights into Heart Failure |
| Q28544014 | miR-185 plays an anti-hypertrophic role in the heart via multiple targets in the calcium-signaling pathways |
Search more.